AGENERASE
LOE ApproachingNDAORALSOLUTION
Approved
Apr 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AGENERASE is an oral solution small-molecule drug approved by GSK in 1999. The specific indication and mechanism of action are not provided in available data, limiting clinical context. This product is approaching loss of exclusivity, indicating it is a mature asset in its lifecycle.
LOE Approaching
Product is in decline phase with moderate competitive pressure (30%), suggesting reduced team investment and potential headcount optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching LOE, AGENERASE offers minimal career growth opportunity. This product is better suited for professionals in transition or seeking stable, lower-visibility roles rather than high-impact career advancement.
Brand ManagerField Sales Representative
Worked on AGENERASE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.